KR20010093140A - 산화적 대사에 대한 감수성이 있는 후보 화합물을스크린하는 방법 - Google Patents
산화적 대사에 대한 감수성이 있는 후보 화합물을스크린하는 방법 Download PDFInfo
- Publication number
- KR20010093140A KR20010093140A KR1020017006953A KR20017006953A KR20010093140A KR 20010093140 A KR20010093140 A KR 20010093140A KR 1020017006953 A KR1020017006953 A KR 1020017006953A KR 20017006953 A KR20017006953 A KR 20017006953A KR 20010093140 A KR20010093140 A KR 20010093140A
- Authority
- KR
- South Korea
- Prior art keywords
- enzyme
- metabolism
- testosterone
- cytochrome
- cyp3a4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 116
- 238000000034 method Methods 0.000 title claims abstract description 81
- 238000012216 screening Methods 0.000 title claims abstract description 19
- 230000004783 oxidative metabolism Effects 0.000 title description 9
- 230000004060 metabolic process Effects 0.000 claims abstract description 78
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims abstract description 68
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims abstract description 68
- 102000004190 Enzymes Human genes 0.000 claims abstract description 51
- 108090000790 Enzymes Proteins 0.000 claims abstract description 51
- 230000002503 metabolic effect Effects 0.000 claims abstract description 31
- 239000002243 precursor Substances 0.000 claims abstract description 26
- 238000007086 side reaction Methods 0.000 claims abstract description 18
- 230000035945 sensitivity Effects 0.000 claims abstract description 10
- 238000001514 detection method Methods 0.000 claims abstract description 4
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 71
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims description 69
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims description 31
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 14
- 241000894007 species Species 0.000 claims description 10
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims description 6
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims description 6
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims description 6
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims description 6
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims description 6
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims description 6
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 3
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 152
- 238000004519 manufacturing process Methods 0.000 description 79
- 229960003604 testosterone Drugs 0.000 description 76
- 230000001404 mediated effect Effects 0.000 description 61
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 48
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 39
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 39
- 239000000758 substrate Substances 0.000 description 37
- 239000003814 drug Substances 0.000 description 26
- XSEGWEUVSZRCBC-UHFFFAOYSA-N 6beta-Hydroxytestosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC(O)C2=C1 XSEGWEUVSZRCBC-UHFFFAOYSA-N 0.000 description 24
- 229960003893 phenacetin Drugs 0.000 description 23
- 239000002207 metabolite Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 238000003556 assay Methods 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 229960004125 ketoconazole Drugs 0.000 description 15
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 14
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 13
- 229960001985 dextromethorphan Drugs 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 230000003647 oxidation Effects 0.000 description 13
- 238000007254 oxidation reaction Methods 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 108010044467 Isoenzymes Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000005284 excitation Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 101150053185 P450 gene Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010517 secondary reaction Methods 0.000 description 5
- 238000002798 spectrophotometry method Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 239000013626 chemical specie Substances 0.000 description 4
- 230000037323 metabolic rate Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- -1 superoxide anions Chemical class 0.000 description 4
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 150000003515 testosterones Chemical class 0.000 description 3
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 2
- XNZRYTITWLGTJS-UHFFFAOYSA-N 7-phenylmethoxyphenoxazin-3-one Chemical compound C1=C2OC3=CC(=O)C=CC3=NC2=CC=C1OCC1=CC=CC=C1 XNZRYTITWLGTJS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 238000000695 excitation spectrum Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003269 fluorescent indicator Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BFZHCUBIASXHPK-QJSKAATBSA-N 11alpha-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2O BFZHCUBIASXHPK-QJSKAATBSA-N 0.000 description 1
- XSEGWEUVSZRCBC-ZVBLRVHNSA-N 6beta-hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3C[C@@H](O)C2=C1 XSEGWEUVSZRCBC-ZVBLRVHNSA-N 0.000 description 1
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 1
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150051438 CYP gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KGQZGCIVHYLPBH-UHFFFAOYSA-N Furafylline Chemical compound O=C1N(C)C(=O)C=2NC(C)=NC=2N1CC1=CC=CO1 KGQZGCIVHYLPBH-UHFFFAOYSA-N 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000529895 Stercorarius Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000003283 colorimetric indicator Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229950004998 furafylline Drugs 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- SQRTWLGWCOJOTO-UHFFFAOYSA-N n-(2-ethoxyphenyl)acetamide Chemical compound CCOC1=CC=CC=C1NC(C)=O SQRTWLGWCOJOTO-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/205,762 US6312917B1 (en) | 1998-12-04 | 1998-12-04 | Method of screening candidate compounds for susceptibility to oxidative metabolism |
| US09/205,762 | 1998-12-04 | ||
| PCT/US1999/027130 WO2000034506A2 (en) | 1998-12-04 | 1999-11-15 | Method of screening candidate compounds for susceptibility to oxidative metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010093140A true KR20010093140A (ko) | 2001-10-27 |
Family
ID=22763550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020017006953A Ceased KR20010093140A (ko) | 1998-12-04 | 1999-11-15 | 산화적 대사에 대한 감수성이 있는 후보 화합물을스크린하는 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6312917B1 (https=) |
| EP (1) | EP1135521B1 (https=) |
| JP (1) | JP2002531138A (https=) |
| KR (1) | KR20010093140A (https=) |
| AT (1) | ATE317914T1 (https=) |
| AU (1) | AU774229B2 (https=) |
| BR (1) | BR9916458A (https=) |
| CA (1) | CA2352523A1 (https=) |
| DE (1) | DE69929900T2 (https=) |
| MX (1) | MXPA01005528A (https=) |
| NZ (1) | NZ512217A (https=) |
| WO (1) | WO2000034506A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632630B2 (en) * | 2000-03-29 | 2003-10-14 | Aclara Biosciences, Inc. | Monooxygenase assays |
| US20050159901A1 (en) * | 2001-04-02 | 2005-07-21 | Astex Technology Limited | Crystal structure of cytochrome P450 |
| US20050032119A1 (en) * | 2001-04-02 | 2005-02-10 | Astex Technology Ltd. | Crystal structure of cytochrome P450 |
| US7148046B2 (en) * | 2001-04-02 | 2006-12-12 | Astex Therapeutics Limited | Crystal structure of cytochrome P450 |
| US20070179716A1 (en) * | 2001-04-02 | 2007-08-02 | Astex Therapeutics Limited | Crystal structure of cytochrome P450 3A4 and uses thereof |
| AU2002365070A1 (en) * | 2001-08-03 | 2003-06-30 | Diversa Corporation | P450 enzymes, nucleic acids encoding them and methods of making and using them |
| DE60214869T2 (de) * | 2001-10-25 | 2007-04-12 | Astex Technology Ltd., Cambridge | Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung |
| US20040053383A1 (en) * | 2001-10-25 | 2004-03-18 | Astex Technology Ltd. | Crystals of cytochrome P450 2C9, structures thereof and their use |
| US20040096874A1 (en) * | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
| US20050164341A1 (en) * | 2002-05-30 | 2005-07-28 | Jose Cosme | Methods of purification of cytochrome p450 proteins and of their crystallizing |
| GB0216203D0 (en) * | 2002-07-12 | 2002-08-21 | Imp Cancer Res Tech | Mondulation of cytochrome P450 reductase activity |
| EP1546162B1 (en) | 2002-09-20 | 2011-06-22 | Promega Corporation | Luminescence-based methods and probes for measuring cytochrome p450 activity |
| WO2004038015A1 (en) * | 2002-10-25 | 2004-05-06 | Astex Technology Limited | Crystal structure of cytochrome p450 3a4 and its use |
| US20040219602A1 (en) * | 2003-03-01 | 2004-11-04 | Symyx Technologies, Inc. | Evaluating effects of exposure conditions on drug samples over time |
| WO2005098025A2 (en) * | 2004-04-05 | 2005-10-20 | The University Of North Carolina At Chapel Hill | High throughput reactive oxygen species-based cytochrome p450 inhibition assay |
| US20060046278A1 (en) * | 2004-08-26 | 2006-03-02 | Qualyst, Inc. | Methods and kits for determining metabolic stability of compounds |
| US20060223135A1 (en) * | 2005-04-05 | 2006-10-05 | The University Of North Carolina At Chapel Hill | High throughput reactive oxygen species-based cytochrome P450 inhibition assay |
| EP2272972A1 (en) | 2005-05-31 | 2011-01-12 | Promega Corporation | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions |
| US20090318561A1 (en) * | 2008-06-23 | 2009-12-24 | Mutual Pharmaceutical Company, Inc. | Colchicine products, method of manufacture, and methods of use |
| US8288559B2 (en) | 2008-08-18 | 2012-10-16 | Promega Corporation | Luminogenic compounds and methods to detect cytochrome P450 3A enzymes |
| US9790537B2 (en) | 2014-01-29 | 2017-10-17 | Promega Corporation | Quinone-masked probes as labeling reagents for cell uptake measurements |
| WO2018118897A1 (en) * | 2016-12-19 | 2018-06-28 | Dice Molecules Sv, Llc | Methods of estimating metabolic stability of tagged combinatorial library compounds |
| WO2024223797A1 (en) | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341868A (en) * | 1978-08-18 | 1982-07-27 | Kyowa Hakko Kogyo Co., Ltd. | Method and test composition for the determination of the substrate for xanthine oxidase |
| WO1980000454A1 (fr) | 1978-08-18 | 1980-03-20 | Kyowa Hakko Kogyo Kk | Methode de mesure d'un substrat de xanthine oxydase et composition pour sa determination |
| JP2515551B2 (ja) * | 1987-06-08 | 1996-07-10 | 和光純薬工業株式会社 | 新規な過酸化水素の定量方法 |
| US5413915A (en) | 1988-07-12 | 1995-05-09 | Resource Technologies Group, Inc. | Method and sensor for detecting toxic chemical exposure effects and metabolic activation of carcinogenic chemical agents |
| AU1970897A (en) | 1996-04-15 | 1997-11-07 | Fox Chase Cancer Center | Assays for detection of purine metabolites |
| GB9821932D0 (en) | 1998-10-09 | 1998-12-02 | Univ Leicester | Cytochrome P450 electrochemical system |
-
1998
- 1998-12-04 US US09/205,762 patent/US6312917B1/en not_active Expired - Fee Related
-
1999
- 1999-11-15 JP JP2000586939A patent/JP2002531138A/ja active Pending
- 1999-11-15 EP EP99957569A patent/EP1135521B1/en not_active Expired - Lifetime
- 1999-11-15 NZ NZ512217A patent/NZ512217A/en not_active IP Right Cessation
- 1999-11-15 BR BR9916458-2A patent/BR9916458A/pt not_active Application Discontinuation
- 1999-11-15 WO PCT/US1999/027130 patent/WO2000034506A2/en not_active Ceased
- 1999-11-15 KR KR1020017006953A patent/KR20010093140A/ko not_active Ceased
- 1999-11-15 AT AT99957569T patent/ATE317914T1/de not_active IP Right Cessation
- 1999-11-15 AU AU15250/00A patent/AU774229B2/en not_active Ceased
- 1999-11-15 MX MXPA01005528A patent/MXPA01005528A/es not_active IP Right Cessation
- 1999-11-15 DE DE69929900T patent/DE69929900T2/de not_active Expired - Fee Related
- 1999-11-15 CA CA002352523A patent/CA2352523A1/en not_active Abandoned
-
2001
- 2001-11-05 US US09/993,842 patent/US20020058295A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1135521A2 (en) | 2001-09-26 |
| ATE317914T1 (de) | 2006-03-15 |
| EP1135521B1 (en) | 2006-02-15 |
| WO2000034506A3 (en) | 2000-11-23 |
| WO2000034506A2 (en) | 2000-06-15 |
| NZ512217A (en) | 2002-03-28 |
| AU1525000A (en) | 2000-06-26 |
| AU774229B2 (en) | 2004-06-17 |
| MXPA01005528A (es) | 2002-04-24 |
| DE69929900T2 (de) | 2006-08-17 |
| US6312917B1 (en) | 2001-11-06 |
| BR9916458A (pt) | 2001-09-04 |
| US20020058295A1 (en) | 2002-05-16 |
| JP2002531138A (ja) | 2002-09-24 |
| DE69929900D1 (de) | 2006-04-20 |
| CA2352523A1 (en) | 2000-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20010093140A (ko) | 산화적 대사에 대한 감수성이 있는 후보 화합물을스크린하는 방법 | |
| Weaver et al. | Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation | |
| Crespi et al. | Fluorometric screening for metabolism-based drug–drug interactions | |
| Chauret et al. | Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe | |
| Tang et al. | Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity | |
| Feidt et al. | Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes | |
| Chauret et al. | The use of 3-[2-(N, N-diethyl-N-methylammonium) ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes | |
| Goddard et al. | Enzyme activity fingerprinting with substrate cocktails | |
| Lahoz et al. | Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry | |
| CN101166831B (zh) | 高密度脂蛋白中的胆固醇的测定方法 | |
| Venhorst et al. | Evaluation of a novel high-throughput assay for cytochrome P450 2D6 using 7-methoxy-4-(aminomethyl)-coumarin | |
| Palamanda et al. | Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies | |
| Duellman et al. | A bioluminescence assay for aldehyde dehydrogenase activity | |
| Nicoll-Griffith et al. | Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes | |
| WO2002004660A2 (en) | Method for testing for inhibition of drug-metabolizing cytochrome p450 isozymes | |
| Rao et al. | ‘Open access’ generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies | |
| Kanoh et al. | An integrated screening system for the selection of exemplary substrates for natural and engineered cytochrome P450s | |
| Chang et al. | Microarray of human P450 with an integrated oxygen sensing film for high-throughput detection of metabolic activities | |
| JP4904298B2 (ja) | ステロイド５α−レダクターゼ活性の測定方法およびそれに用いるキット | |
| J. Waxman et al. | Use of 7-Ethoxycoumarinto Monitor Multiple Enzymesin the Human CYP1, CYP2, and CYP3 Families | |
| US20060046278A1 (en) | Methods and kits for determining metabolic stability of compounds | |
| WO2007011778A2 (en) | Use of raman spectroscopy in enzyme activity assays | |
| JP2008206451A (ja) | 薬物代謝能力を有する酵素を不可逆的に阻害する能力を検定する方法 | |
| Waxman et al. | Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation | |
| US20060223135A1 (en) | High throughput reactive oxygen species-based cytochrome P450 inhibition assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20010602 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20041115 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060331 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20060822 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060331 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |